anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
678,109. Making a therapeutic substance. CHEMICAL HORMONE CORPORATION. March 24, 1950, No. 7417/50. Class 81 (i). A therapeutic substance capable of affecting the concentration of cholesterol or phospholipids in the blood of mammals is prepared by treating an organ from the glandular or central nervous system of mammals, bird or fishes, at a pH between 7 and 7.6 with petroleum ether, ethyl ether, a liquid water-miscible monohydric alcohol, or polyhydric alcohol, a ketone, or a mixture of such solvents, the alcohols and ketones having no functional groups other than hydroxyl or carbonyl groups, removing the fraction soluble in said solvent, removing said solvent, adding chloroform to the resulting residue, separating the chloroform insoluble residue from the resulting mixture, and subjecting a solution of the chloroform insoluble portion to chromatographic separation. The chromatographic column may be made of alumina, gelatin, calcium carbonate, or silica. The spent column can be cut into four portions differentiated by colour and leached with solvents to give four substances having different effects on the cholesterol and phosphilipoid concentrations in the blood. Specified starting materials are the anterior or posterior pituitary glands, liver, adrenals, pancreas, brain or spinal cord of cattle, sheep, hogs, chickens, ducks and sharks. Examples of water-miscible solvents are methanol, ethanol, propanol, isopropanol, butanol, pentanol, acetone, methyl isobutyl ketone, ethylene glycol and propylene glycol. The products of the invention may be further purified by treatment by further chromatographic separation, and may be dissolved in an oily medium such as peanut oil, olive oil, sesame oil or sweet almond oil for administration.
Everolimus (RAD001) 4.5 mg/m² daily over 12 months. Patients will be on Everolimus (RAD001) therapy for 12 months; discontinuation can be necessary due to intolerable toxicity, withdrawal of consent, death or termination of the trial. After 12 months treatment is stopped. If there is progress of disease (see below) after end of therapy, re-start with Everolimus (RAD001) on a compassionate use is possible.
The invention relates to the field of hygiene products. A wet tissue comprises a non-woven fabric substrate, wherein a bacteriostat liquid is dipped into the non-woven fabric substrate; and the non-woven fabric substrate comprises a quaternary ammonium salt compound, a surfactant and a complexing agent. The wet tissue is used for cleaning and sterilizing of cell culture clean rooms and hands, has broad spectrum bacteriostat, can effectively kill and inhibit gram-negative bacteria, positive bacteria, escherichia coli, candida albicans, staphylococcus aureus, yeast and fungi and mycoplasma and the like. The wet tissue is incombustible, difficult to volatilize, safe to use, transport and use. The wet tissue is harmless to a human body and cells, is not likely to affect cell culture and human body health. The wet tissue has excellent compatibility and no corrosion to glass, metal and plastic. The bacteriostat liquid contains the combination of a surfactant and a complexing agent, the acting time is long, a protection film can be formed on the surface after using, thereby avoiding re-pollution.
Carotinoid emulsions are prepd. as in parent patent but keeping to the following order of addition: soaps of tris-(hydroxymethyl)-aminomethane and opt. satd. fatty acids (9-20C) are mixed with diluents at 30 degrees C-melting point of the soaps, adding the carotinoid to the warm emulsion and then adjusting the carotinoid concentration to up to 4% by adding warm water. The diluents used are either polyoxethylated castor oil, or propyleneglycol and/or polyethyleneglycolethylether. Diluents may contain vit A-palmitate esp. when using beta-carotin. The emulsions are stable completely miscible with water and their viscosity can thus be adjusted.
BACKGROUND: Myocardial infarction (MI) leads to enhanced activity of cardiac fibroblasts (CFs) and abnormal deposition of extracellular matrix proteins, resulting in cardiac fibrosis. Tartrate-resistant acid phosphatase 5 (ACP5) has been shown to promote cell proliferation and phenotypic transition. However, it remains unclear whether ACP5 is involved in the development of cardiac fibrosis after MI. The present study aimed to investigate the role of ACP5 in post-MI fibrosis and its potential underlying mechanisms.
METHODS: Clinical blood samples were collected to detect ACP5 concentration. Myocardial fibrosis was induced by ligation of the left anterior descending coronary artery. The ACP5 inhibitor, AubipyOMe, was administered by intraperitoneal injection. Cardiac function and morphological changes were observed on Day 28 after injury. Cardiac CFs from neonatal mice were extracted to elucidate the underlying mechanism in vitro. The expression of ACP5 was silenced by small interfering RNA (siRNA) and overexpressed by adeno-associated viruses to evaluate its effect on CF activation.
RESULTS: The expression of ACP5 was increased in patients with MI, mice with MI, and mice with Ang II-induced fibrosis in vitro. AubipyOMe inhibited cardiac fibrosis and improved cardiac function in mice after MI. ACP5 inhibition reduced cell proliferation, migration, and phenotypic changes in CFs in vitro, while adenovirus-mediated ACP5 overexpression had the opposite effect. Mechanistically, the classical profibrotic pathway of glycogen synthase kinase-3β (GSK3β)/β-catenin was changed with ACP5 modulation, which indicated that ACP5 had a positive regulatory effect. Furthermore, the inhibitory effect of ACP5 deficiency on the GSK3β/β-catenin pathway was counteracted by an ERK activator, which indicated that ACP5 regulated GSK3β activity through ERK-mediated phosphorylation, thereby affecting β-catenin degradation.
CONCLUSION: ACP5 may influence the proliferation, migration, and phenotypic transition of CFs, leading to the development of myocardial fibrosis after MI through modulating the ERK/GSK3β/β-catenin signaling pathway.
Due to the prevalence of treatment-related health concerns and increased risk of developing metabolic syndrome, recurrence and cardiovascular disease, breast cancer survivors may require diagnostic, therapeutic, supportive or palliative services for many years post-diagnosis. Encouraging breast cancer survivors to adopt a healthy lifestyle post-treatment may reduce the healthcare burden resulting from treatment-related sequelae and improve survival. In particular, higher levels of physical activity (PA) may positively influence some of these side-effects of treatment, enhance quality of life and reduce risk of recurrence and all-cause and breast cancer-related mortality. However, PA levels are generally low among breast cancer survivors and many women decrease their PA following diagnosis. Therefore, interventions are required to improve the post-diagnosis PA levels of breast cancer survivors.

Randomised controlled trials (RCTs) have found improvements in cardiorespiratory fitness, HRQoL, fatigue and weight maintenance in breast cancer survivors participating in PA interventions compared with control groups. However, most of these RCTs utilised facility-based interventions, which may limit their patients who have trouble accessing exercise facilities due to transportation or time-related difficulties. To overcome these problems home-based PA interventions have been investigated and have generally reported good adherence and positive effects on health, fitness and HRQoL outcomes. However, there is a lack of relevant interventions in the United Kingdom.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic whose dispersibility can be enhanced without using a surfactant and which can exhibit an excellent UV screening effect, an uniform finish and excellent transparency, by formulating an oil phase, a specific powdery component and an amphipathic dispersant. SOLUTION: This two-layered liquid sunscreen cosmetic comprises (A) an oil phase, (B) a powdery component containing at least particulate titanium dioxide and/or particulate zinc oxide, and (C) an amphipathic dispersant (preferably a higher fatty acid). It is preferable to use a volatile oil such as a low boiling point isoparaffin or a low boiling point silicone oil as the oil in the component A. The component B preferably has an average particle diameter of <=0.10 μm. The cosmetic preferably furthermore contains cross-linked elastic organopolysiloxane powder, clay mineral-based powder, an oil-soluble resin, and the like. Thereby, the objective cosmetic which has a good powder- redispersing property and can homogeneously be mixed when shaken in use can be provided.
BACKGROUND Preliminary data suggest an adipogenic role for growth arrest-specific 6 (Gas6), a pleiotropic molecule involved in inflammation, proliferation, and hemostasis through its Tyro3, Axl, and MerTK (TAM) receptors. This study compares Gas6 expression in plasma and visceral and subcutaneous adipose tissue in 42 adults with obesity (body mass index ≥40 kg/m²) and 32 normal-weight controls to elucidate its role in obesity and related metabolic alterations. MATERIAL AND METHODS Using a case-control design, we measured Gas6 levels in plasma via a validated sandwich enzyme-linked immunosorbent assay and in adipose tissues through quantitative polymerase chain reactio with specific probes. Medians and correlations were analyzed using Mann-Whitney and Spearman tests. A general linear model assessed the impact of covariates on the Gas6-anthropometric relationship, with statistical significance determined by P values. RESULTS Plasma Gas6 levels were significantly higher in the obese group than in controls (P=0.0006). While Gas6 mRNA expression did not significantly differ in subcutaneous adipose tissue between groups, it was notably higher in visceral than subcutaneous adipose tissue in controls (P<0.05). A significant correlation was found between plasma Gas6 levels and body mass index (P=0.001). CONCLUSIONS Gas6 plasma levels are elevated in morbid obesity, particularly in visceral adipose tissue, and are linked to altered glucose tolerance in female patients. These findings highlight the role of Gas6 in obesity-related metabolic complications and suggest avenues for further research and potential therapies.
Cprofol is administered at a rate of 3mg/kg\*h for patient induction. After 60 seconds, a sedation assessment is initiated until the patient loses consciousness.Then adjust the propofol dose to 1mg/kg/h and make further dose adjustments based on the patient's response, with increments or decrements ranging from 0.2mg/kg/h, within a total range of 0.6-1.6mg/kg/h.
BACKGROUND: The implementation of the pathologic CRM (circumferential resection margin) staging system for pancreatic head ductal adenocarcinomas (hPDAC) resulted in a dramatic increase of R1 resections at the dorsal resection margin, presumably because of the high rate of mesopancreatic fat (MP) infiltration. Therefore, mesopancreatic excision (MPE) during pancreatoduodenectomy has recently been promoted and has demonstrated better local disease control, fueling the discussion of neoadjuvant downsizing regimes in MP + patients. However, it is unknown to what extent the MP is infiltrated in patients with distal pancreatic (tail/body) carcinomas (dPDAC). It is also unknown if the MP infiltration status affects surgical margin control in distal pancreatectomy (DP). The aim of our study was to histopathologically analyze MP infiltration and elucidate the influence of resection margin clearance on recurrence and survival in patients with dPDAC. Furthermore, the results were compared to a collective receiving MPE for hPDAC.
METHOD: Clinicopathological and survival parameters of 295 consecutive patients who underwent surgery for PDAC (n = 63 dPDAC and n = 232 hPDAC) were evaluated. The CRM evaluation was performed in a standardized fashion and the specimens were examined according to the Leeds pathology protocol (LEEPP). The MP area was histopathologically evaluated for cancerous infiltration.
RESULTS: In 75.4% of dPDAC patients the MP fat was infiltrated by vital tumor cells. The rates of MP infiltration and R0CRM- resections were similar between dPDAC and hPDAC patients (p = 0.497 and 0.453 respectively). MP- infiltration status did not correlate with CRM implemented resection status in dPDAC patients (p = 0.348). In overall survival analysis, resection status and MP status remained prognostic factors for survival. In follow up analysis. surgical margin clearance in dPDAC patients was associated with a significant improvement in local recurrence rates (5.2% in R0CRM- resected vs. 33.3 in R1/R0CRM + resected, p = 0.002).
CONCLUSION: While resection margin status was not affected by the MP status in dPDAC patients, the high MP infiltration rate, as well as improved survival in MP- dPDAC patients after R0CRM- resection, justify mesopancreatic excision during splenopancreatectomy. Larger scale studies are urgently needed to validate our results and to study the effect on neoadjuvant treatment in dPDAC patients.
Risk Summary

Based on findings in animal studies, Kepivance may cause fetal harm when administered to pregnant women. There are no data available on Kepivance use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, intravenous administration of palifermin to pregnant rabbits and rats during the period of organogenesis resulted in embryo-fetal mortality and alterations to growth [see Data]. 

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. 

Data

Animal data

In embryo-fetal development studies, palifermin was administered intravenously to pregnant rabbits and rats during the perid of organogenesis. Doses were 5, 60, and 150 μg/kg/day in rabbits (gestation days 6-18) and 100, 300, and 1000 μg/kg/day in rats (gestation days 6 through 17). Increased post-implantation loss and decreased fetal body weights occurred along with maternal toxicity (clinical signs and reductions in body weight gain and food consumption) at doses of 150 μg/kg/day in rabbits and 1000 μg/kg/day in rats. Increased skeletal variations was noted in rats at 1000 μg/kg/day. Doses of 150 μg/kg/day in rabbits and 1000 μg/kg/day in rats are approximately 5-times (rabbits) and 35-times (rats) the exposure (AUC) in patients receiving the recommended dose of 60 μg/kg/day.
The invention aims to provide traditional Chinese medicine micropowder granules which can treat appendicitis and relive pain for appendicitis patients. The invention relates to a micron traditional Chinese medicine which is prepared from traditional Chinese medicines by utilizing a super-micronization technology. The medicine is prepared from six traditional Chinese herbal medicines of honeysuckle, angelica, figwort, lilyturf root, pearl barley and liquorice through super-micronization. Appendicitis is a common disease and a frequently encountered disease, gives priority to surgical treatment at present, and causes great pain and economic burden on the patients. Therefore, the appendicitis patients hope to seek a traditional Chinese patent medicine preparation with accurate curative effect and convenient use for treating appendicitis. The medicine has the following advantages: 1. the medicine is suitable for the treatment and the auxiliary treatment of various appendicitis; 2. the medicine has accurate curative effect, no toxicity or side effect and addresses both the symptoms and root causes; 3. the medicine avoids surgery and relieves the pain and burden of the patients; and 4. the medicine has special process preparation and high bioavailability.
Children will be administered a number of neuropsychological tests. Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL, Generic Scale and Diabetes Module), diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
The current guidelines provide indications for primary prevention implanted cardioverter defibrillator (ICD) therapy based on left ventricle ejection fraction (LVEF) and New York Heart Association (NYHA) class. This strategy is able to intercept only part of fatal arrhythmic events and, on the other hand, led to useless ICD implantations mainly among those patients with severe heart failure (HF) who will never incur in sever arrhythmias but rather will die because of decompensated HF. Cardiac magnetic resonance offers the possibility of identifying and quantitatively assessing myocardium fibrosis both localized in a specific area and diffuse and has already proved a significant prognostic meaning. DERIVATE is a prospective, international, multicenter, observational registry of stable HF patients with reduced LVEF who underwent clinical evaluation, transthoracic echocardiography (TTE) and cardiac magnetic resonance (CMR). Specifically, the primary aim of DERIVATE is to determine CMR findings that predict outcomes, with incremental value over LVEF and NYHA classification.

The DERIVATE registry uses a collaborative design with contribution and merger of similar prospectively enrolled cohorts from 33 sites in 6 countries in Europe and North America. The targeted population for the DERIVATE registry is a large sample of patients with clinical history of chronic HF who have undergone CMR by referral physician. Indication for CMR exams was recorded and classified according to the known causes of HF. All DERIVATE study patients are followed for all-cause mortality, sudden cardiac death (SCD), cardiovascular death (including death caused by acute myocardial infarction and stroke), sustained ventricular tachycardia (VT), aborted SCD, hospitalization or cardiac death related to chronic HF. The follow up minimum period is 12 months. Complete risk factors, clinical presentation, echocardiography and CMR data recording, and follow-up for all-outcomes will contribute data for common analysis.
Participants will undergo a diagnostic test with a single weight-adapted dose of oral urea first. After a a wash-out phase of at least 3 days and not more than 28 days participants will undergo a second diagnostic test with a single weight-adapted dose of placebo.
Water-soluble pressure-sensitive adhesives include a water-soluble polymer that is made tacky at room temperature by addition of a water-soluble plasticizer that is miscible with the polymer. Suitable polymers are solid at room temperature; and have a hydrophilicity as measured by water uptake greater than about 25 %; they are liquid at room temperature and have a boiling point higher than about 80 °C. The adhesives according to the invention may conveniently be provided in dry film form. Preferred water-soluble pressure-sensitive adhesives of the invention adhere both to mucosal surfaces and to a variety of materials that may constitute a part of a device or prosthesis to be held in a body cavity that has a mucosal lining. Also, a laminated device for the controlled release of a substance within a mucosa-lined body cavity includes the substance dissolved or dispersed in either or both of a water-soluble pressure-sensitive adhesive layer and optionally one or more water-soluble polymer layers. Also, devices for administering a substance over an extended time for relief of sore throat or cough, or for administering a breath freshening agent, particularly a mint odorant, include a water soluble polymer film layer containing the active ingredient, and a water soluble pressure sensitive mucoadhesive layer.
Aim: To assess the effect of moxa smoke in the treatment using moxibustion for knee osteoarthritis.

Design: This is a multicentre, randomised, single blinded, parallel-group design clinical trial. 138 eligible participants will be randomly allocated into 2 groups (moxibustion group or smoke-free moxibustion group) with a 1:1 allocation ratio, and receive 12 sessions of moxibustion treatment over a period of 4 weeks, three sessions per week. Each session will last 30 minutes. The whole study period is 13 weeks, with a 1 week run in period, 4 week treatment phase, and 8 week follow-up phase.The participants will receive moxibustion treatment at three acupoints (EX-LE04,ST35,ST36). In moxa-free smoke moxibustion group, investigators place a purification device(Shenzhen Conyson Electronic Technology Co, Ltd,C200 moxa smoke purification device,Shenzhen,China) at the top of the moxibustion to remove the moxa smoke. The primary measurement outcomes are the mean change in the global scale value of the Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) pain and function scores from baseline to 4 weeks. The secondary outcomes are the Visual Analogue Scale (VAS) and the patient global assessment. Investigators will assess participants at the second visit (before starting moxibustion treatment) and at the 2, 4, 8, and 12 week respectively after the baseline.
<P>PROBLEM TO BE SOLVED: To obtain a vaccine effective for prevention and treatment of feline infectious peritonitis (FIP).  <P>SOLUTION: This vaccine for the FIP is obtained by using an N-protein having a specific structure or a fragment thereof as an antigen. The desirable antigen is the N-protein derived from a specified virus type I strain (KU-2). The vaccine containing the N-protein provides preventive effects on wide FIPV. The N-protein is highly safe because of being free from an infection-enhancing epitope. The N-protein can achieve the preventive effects on a virus type I which causes 70% of the actual FIP.  <P>COPYRIGHT: (C)2004,JPO
PURPOSE:To obtain a bathing agent by converting an oil of HINOKI (Chamaecyparis obtusa Endl.) extracted from the HINOKI produced in Japan into an aqueous dispersion system with a surfactant and making the oil of the HINOKI readily soluble in bath water. CONSTITUTION:This bathing agent is obtained by mixing 100 pts.wt. oil of HINOKI extracted from the HINOKI produced in Japan with 1-50 pts.wt., preferably 5-30 pts.wt. surfactant and stirring the resultant mixture at 10-70 deg.C temperature for about several min to 5hr with a homogenizer. The bathing agent is directly dispersed in bath water by dripping thereof into the bath water and spreading a fragrance over the whole bathroom. A nonionic surfactant is preferred as the surfactant and, e.g. a sucrose ester, a polyglycerol ester, a propylene glycol ester and a sorbitan ester of a fatty acid are cited as the surfactant. The atmosphere of a HINOKI bath can be enjoyed by the bathing agent which has effects on sufficient relaxation of the mind and body by synergistic effects of forest bathing with bathing effects.